Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Roche Holding AG

Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks.

Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche

Palantir Technologies

Vertiv Holdings Co

Advanced Micro Devices (NASDAQ: AMD ) stock has been heating up for July. The top rival of Nvidia (NASDAQ: NVDA ) recently announced its intent to acquire Silo AI in an all-cash deal worth around $665 million.

3 Hot Growth Stocks That Will Make You Forget About AMD

Merck

Pfizer

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.

4 Large Drug Stocks to Watch as Innovation, M&A Pick Up

Novo Holdings, the main shareholder of Novo Nordisk (NYSE:NVO), has led a $100 million Series C funding round for Swiss company Asceneuron, which is developing a next-generation treatment for Alzheimer's. ASN51 is an oral small molecule drug targeting intracellular tau, protein tangles inside nerve cells, which could potentially revolutionize Alzheimer's treatment, according to Novo's senior partner Naveed Siddiqi.

Novo Nordisk investor backs $100m Alzheimer's funding round

Digital Realty Trust

Equinix

NVIDIA

Occidental Petroleum

Taiwan Semiconductor Manufacturing

Investors should look for top-quality stocks for the remainder of the year. With plenty of uncertainties, a nearing presidential election, geopolitical issues, and a lack of a clear economic trajectory, you want to make sure the stock you're jumping into is top-quality and fundamentally solid.

7 Top-Quality Stocks to Buy Now: July 2024

Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.

Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford

Novo Nordisk is already developing its next set of weight loss therapies. At least one market research firm is incredibly optimistic about its prospects.

Here's 80 Billion More Reasons to Buy Novo Nordisk Stock

Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market

Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive problems, according to an observational study published by researchers at Oxford University.

Ozempic linked with lower dementia risk, nicotine use, British study finds

Novo Nordisk stock has been chugging sideways for weeks, and continues to trade in a 5% buy zone after a June breakout.

Ozempic Maker Novo Nordisk Trades Quietly, Constructively

Novo Nordisk stock popped Friday after a study showed its diabetes and weight-loss drug could lower the risk of developing dementia.

Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study

American depositary receipts (ADRs) of Novo Nordisk (NVO) rose in intraday trading Friday after the release of an Oxford study that showed the Danish company's Ozempic diabetes drug was linked to lower rates of dementia and a range of mental problems.

Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates

The study looked at semaglutide, the scientific name for Novo Nordisk's NVO, -2.07% NOVO.B, +0.52% Ozempic, with the intent of looking at whether it caused neurological problems. Instead, it found a 48% decline in dementia relative to those who took sitagliptin, Merck's diabetes drug that's known as Januvia.

Study finds Novo Nordisk's Ozempic may reduce dementia

MoneyWeek columnist Bill Bonner wrote in the June 28 edition of the U.K. financial publication that the two men running for president of the United States are perfect candidates for a nation in decline. That got me thinking about global stocks.

3 Global Stocks Worth Buying as America Stumbles

GlaxoSmithKline

Novartis

Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.

The 3 Most Undervalued Pharma Stocks to Buy in July 2024

Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.

Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?

Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.

Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec

The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.

US FDA declines to approve Novo Nordisk's weekly insulin

Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.

Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugmaker over how much it charges compared to prices in other countries.

US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices

Moderna

Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed financial results.

3 Pharma Stocks That Could Make Your Grandchildren Rich

Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior official said on Wednesday.

Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.

Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug

The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) slipping.

Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective

Novo Nordisk (NYSE:NVO) shares fell and Eli Lilly and Co (NYSE:LLY) rose after a study found the US company's weight-loss drug may be more effective.  Lilly's tirzepatide, branded as Mounjaro, was pitted against semaglutide, which Novo Nordisk (NYSE:NVO) makes under the Wegovy higher-dose brand for weight loss and Ozempic for type-2 diabetes, though the patients in the trial were all taking Ozempic.

News for Novo Nordisk Stock (NVO)